Dewpoint Therapeutics succeeds in the nomination of DPTX3496 as their second development candidate!

Feb 19

Written By Kimberly Hicks

Kimberly Hicks

GSS Shares 2024 Year in Review

Exciting news! Our client, Dewpoint Therapeutics, has been recognized as “One to Watch” by The Pharma Letter.